Fibrinolysis and diabetes

被引：12

作者：

Sobel, BE ^{[1
]}

机构：

[1] Univ Vermont, Coll Med, Dept Med, Burlington, VT 05405 USA

来源：

FRONTIERS IN BIOSCIENCE-LANDMARK | 2003年 / 8卷

关键词：

coronary artery disease; atherosclerosis; diabetes mellitus; insulin resistance; plasminogen activator inhibitor type-1; coagulation and fibrinolytic systems; review;

D O I：

10.2741/1140

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Diabetes is characterized by impaired fibrinolysis. This phenomenon reflects augmented concentrations of plasminogen activator inhibitor type-1 in tissues and in blood. The derangement appears to depend in part on elevated concentrations of free fatty acids, triglycerides, and insulin in association with the insulin resistance syndrome. Impaired fibrinolysis may exacerbate already existing coronary artery disease and potentiate its evolution. Several measures are available to favorably modify fibrinolytic system capacity. They include inhibition of the renin angiotensin system, attenuation of dyslipidemia, and enhancement of insulin sensitivity. Accordingly, normalization of the derangement in fibrinolysis typical of diabetes is an important and achievable therapeutic objective.

引用

页码：D1085 / D1092

页数：8

共 58 条

[1] Production of plasminogen activator inhibitor 1 by human adipose tissue - Possible link between visceral fat accumulation and vascular disease [J].

Alessi, MC ;

Peiretti, F ;

Morange, P ;

Henry, M ;

Nalbone, G ;

JuhanVague, I .

DIABETES, 1997, 46 (05) :860-867

[2] Reduced early insulin secretion in the etiology of type 2 diabetes mellitus in Pima Indians [J].

Bogardus, C ;

Tataranni, PA .

DIABETES, 2002, 51 :S262-S264

[3] ATTENUATION OF THE SYNTHESIS OF PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 BY NIACIN - A POTENTIAL LINK BETWEEN LIPID-LOWERING AND FIBRINOLYSIS [J].

BROWN, SL ;

SOBEL, BE ;

FUJII, S .

CIRCULATION, 1995, 92 (04) :767-772

[4] MEMBRANE FLUIDITY MEMBRANE LIPID PATTERN AND CYTOSOLIC CA2+ CONTENT IN PLATELETS FROM A GROUP OF TYPE-II DIABETIC-PATIENTS WITH MACROVASCULAR COMPLICATIONS [J].

CAIMI, G ;

VENTIMIGLIA, G ;

PRESTI, RL ;

ROMANO, A ;

MONTANA, M ;

CATANIA, A ;

CANINO, B ;

SARNO, A .

DIABETES CARE, 1995, 18 (01) :60-63

[5] Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects [J].

Calles-Escandon, J ;

Mirza, SA ;

Sobel, BE ;

Schneider, DJ .

DIABETES, 1998, 47 (02) :290-293

[6] Amelioration of the inhibition of fibrinolysis in elderly, obese subjects by moderate energy intake restriction [J].

CallesEscandon, J ;

Ballor, D ;

HarveyBerino, J ;

Ades, P ;

Tracy, R ;

Sobel, B .

AMERICAN JOURNAL OF CLINICAL NUTRITION, 1996, 64 (01) :7-11

[7] Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation - A gene targeting and gene transfer study in mice [J].

Carmeliet, P ;

Moons, L ;

Lijnen, HR ;

Janssens, S ;

Lupu, F ;

Collen, D ;

Gerard, RD .

CIRCULATION, 1997, 96 (09) :3180-3191

[8]

CEFALU WT, IN PRESS DIABETES CA

[9]

CHEN Y, IN PRESS NUTR METABO

[10] Introduction: Risks and benefits of intensive management in non-insulin-dependent diabetes mellitus - The Fifth Regenstrief Conference [J].

Clark, CM ;

Vinicor, F .

ANNALS OF INTERNAL MEDICINE, 1996, 124 (01) :81-85

← 1 2 3 4 5 6 →